Ulrich Steidl, M.D., Ph.D., professor and chair of cell biology at Albert Einstein College of Medicine and deputy director at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center, has been elected a member of the Association of American Physicians (AAP), a prestigious 140-year-old honorary society dedicated to advancing medical knowledge through basic and clinical science.

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the immune system, called adaptive NK cells, to remember ovarian tumours and effectively attack them. The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies for difficult-to-treat cancers.

The role of radiosurgery in the treatment of grade 2 meningioma remains unclear. This study aimed to evaluate the long-term outcomes of gamma knife radiosurgery (GKRS) in patients with grade 2 meningiomas and to identify factors influencing tumor control and survival.

BUFFALO, NY – April 28, 2025 – A new research paper was published in Oncotarget, Volume 16, on April 24, 2025, titled “PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region.”

A new study in Engineering presents GlycoPro, a high-throughput sample-processing platform for multi-glycosylation-omics analysis. It overcomes limitations of existing methods, efficiently processes a large number of samples, and shows promise in breast cancer biomarker discovery, with potential for broader applications in glycosylation-related diseases research.

Cancer continues to pose a substantial public health problem in Nigeria, characterized by rising rates of occurrence and mortality. While there is increasing interest in using natural products for cancer treatment, comprehensive data on the specific bioactive compounds in these plants and how they modulate different types of cancer are still lacking. Additionally, although traditional knowledge about these food plants is rich and valuable, it has not been fully integrated with modern scientific research to create standardized treatment protocols. Scientific databases like PubMed, ScienceDirect, Google Scholar, and ResearchGate were explored to retrieve empirical data. The key plants discussed are Spondias mombin, Xanthosoma sagittifolium, Elaeis guineensis, Irvingia gabonensis, Allium cepa, Blighia sapida, Dioscorea dumetorum, Psidium guajava, and Talinum triangulare. These plants demonstrate a wide range of anticancer properties, including the ability to induce apoptosis (cell death), halt the cell cycle, inhibit angiogenesis, and regulate inflammatory responses. They contain a variety of phytochemicals, such as flavonoids, tannins, terpenoids, alkaloids, and organosulfur compounds, which contribute to their anticancer effects. For example, Spondias mombin contains flavonoids that inhibit the formation of tumors, whereas Xanthosoma sagittifolium exhibits cytotoxic effects against leukemia cells. Additionally, Elaeis guineensis exhibits antioxidant properties that counteract oxidative stress, a crucial factor in cancer progression. This review highlights the significance of these plants in developing complementary cancer therapies that can be used alongside conventional treatments. By combining traditional knowledge with contemporary scientific methods, these medicinal plants have the potential to provide innovative approaches to cancer prevention and treatment, addressing the pressing demand for safer and more efficient therapeutic alternatives.